TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03738345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFNC flow
Description: HFNC flow will be titrated based on the hospital's policy or protocol for hypoxemic patients and research protocol for healthy volunteers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFNC flow
Description: HFNC flow will be titrated based on the hospital's policy or protocol for hypoxemic patients and research protocol for healthy volunteers
Study: NCT04283331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proparacaine Ophthalmic
Description: Each subject will have one eye randomized to receive a bandage contact lens soaked in anesthetic solution (proparacaine hydrochloride 0.5%) and the following eye will serve as a control and receive a bandage soft contact lens soaked in balanced salt solution, which is the current standard of care for PRK.
Study: NCT03307759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy (SABR)
Description: Radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy (SABR)
Description: Radiotherapy
Study: NCT02237313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychological support and therapeutic education program
Study: NCT01614535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: up-and-down method to find out effective concentration of remifentanil for preventing cough during emergence
Description: Targeted effect-site TCI remifentanil for preventing cough effectively during emergence from general anesthesia. For effect-site TCI of remifentanil, a TCI pump was used and pump operation was based on Minto and colleagues' pharmacokinetic model. By Dixon's up-and-down method, the predetermined effect-site concentration(Ce) of remifentanil was determined according to the cough response of the previous patient. The initial target Ce of remifentanil for the first patient was 2.0 ng/ml. If the patients did not cough throughout the peri-extubation period, the predetermined Ce of remifentanil for the subsequent patient was decreased by 0.4 ng/ml. If the patient coughed anytime around extubation, the predetermined Ce for the subsequent patient was increased by 0.4 ng/ml. The stopping rule, as well as for the requirement of at least six turning points in the same direction of the sequential allocation response graph, required the recruitment of more than 20 patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: up-and-down method to find out effective concentration of remifentanil for preventing cough during emergence
Description: Targeted effect-site TCI remifentanil for preventing cough effectively during emergence from general anesthesia. For effect-site TCI of remifentanil, a TCI pump was used and pump operation was based on Minto and colleagues' pharmacokinetic model. By Dixon's up-and-down method, the predetermined effect-site concentration(Ce) of remifentanil was determined according to the cough response of the previous patient. The initial target Ce of remifentanil for the first patient was 2.0 ng/ml. If the patients did not cough throughout the peri-extubation period, the predetermined Ce of remifentanil for the subsequent patient was decreased by 0.4 ng/ml. If the patient coughed anytime around extubation, the predetermined Ce for the subsequent patient was increased by 0.4 ng/ml. The stopping rule, as well as for the requirement of at least six turning points in the same direction of the sequential allocation response graph, required the recruitment of more than 20 patients.
Study: NCT00421707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW876008

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW876008

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03353831

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered by intravenouse route at a dose of 10mg/kg q14 during the treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered by intravenouse route at a dose of 10mg/kg q14 during the treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by intravenous route at a dose of 840 mg q14 during the treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy (Paclitaxel or PLD) will be administered by intravenous route at different doses during the treatment period q28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy (Paclitaxel or PLD) will be administered by intravenous route at different doses during the treatment period q28

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo will be administered by intravenous route q14 during the treatment period
Study: NCT03466996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: More frequent follow up with face to face interaction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care group
Description: Transition goal setting during annual follow up.
Study: NCT01498367

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemonitoring of patients with diabetes type 2
Description: Telemonitoring of the patients's blood glucose level measurements using a the tele-glucose meter
Study: NCT04262817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine form
Description: participants will receive 36mg/ml nicotine salt and freebase nicotine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine form
Description: participants will receive 36mg/ml nicotine salt and freebase nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette experimental flavor
Description: Participants will receive menthol and tobacco flavored e-cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette experimental flavor
Description: Participants will receive menthol and tobacco flavored e-cigarettes
Study: NCT01948908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam
Description: Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam
Description: Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam
Description: Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).
Study: NCT02705560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cow´s milk (3.9% fat, pasteurized)
Description: 600 ml full fat milk (organic, pasteurized, 400 kcal)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hard, yellow cheese
Description: 100 g Swiss cheese (Le Gruyère medium ripe, 400 kcal)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soy based drink
Description: 600 ml Soy drink (540 ml soy milk (232 kcal) supplemented with 60 ml soy and plant based cream (167 kcal)
Study: NCT02819206

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: Detection of bacteria will be performed on a blood sample
Study: NCT03845569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary protein intake reduction
Description: Following two days of controlled diet at 2.2g/kg/d of dietary protein, intake was reduced to 1.2g/kg/d for five days, and protein metabolism was measured on days 1, 3, and 5.

Intervention type: OTHER
Group type: OTHER
Intervention: Three day Controlled Diet
Description: Three days of a controlled diet providing 2.2g/kg/d of dietary protein with protein metabolism measured on day 3. This was used to model the habitual intake of this cohort.
Study: NCT01685164

Intervention type: OTHER
Intervention: Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.
Description: Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.

Intervention type: OTHER
Intervention: Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.
Description: Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.
Study: NCT02520284

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Andecaliximab 150 mg administered via SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Andecaliximab 150 mg administered via SC injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Andecaliximab
Description: Andecaliximab 150 mg administered via SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to andecaliximab administered via SC injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to andecaliximab administered via SC injection
Study: NCT03268122

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Contact Isolation
Description: With regards to MRSA and VRE, the wearing of gowns and gloves will be required for all staff entering a patient room if the patent has an infection or colonization with MRSA or VRE or a recent history (within 90 days) of either

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Targeted Contact Isolation
Description: With regards to MRSA and VRE, the wearing of gowns and gloves will be required for all staff entering a patient room if the patient has an active, highly-transmissible infection with MRSA and/or VRE.~A highly-transmissible infection is defined as one with uncontained secretions or excretions (diarrhea, vomiting, or open draining wounds) or pneumonia.
Study: NCT02790268

Intervention type: PROCEDURE
Intervention: Lens Subluxation Surgery
Description: Surgical Intervention to include Cionni Ring implantation and in-the-bag IOL implantation
Study: NCT01477320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole 40 mg IV daily and tube feed.
Description: Patients randomized to the control group active Comparator will receive tube feed plus an Pantoprazole 40 mg IV daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and tube feed
Description: Patients randomized to Placebo group placebo Comparator will receive tube feed plus an Placebo.
Study: NCT02968732

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Cystectomy
Study: NCT04597528

Intervention type: OTHER
Intervention: Elective Induction
Description: All patients admitted to the labour room would be approached to be enrolled in the study.~Those satisfying the inclusion and exclusion criteria would be prospectively enrolled to the study after procuring an informed consent. If a patient appears to meet the criteria for the study, she will be told about the study and asked for written informed consent to participate. Consent may be obtained anytime from 34 weeks 0 days to 38 weeks 6 days of gestation. Data would be procured on a pre set proforma, entered in real time and safely stored.~The data would later be abstracted to an excel sheet.
Study: NCT02331251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin
Study: NCT01251250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: azadirachta indica
Description: Given orally

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Correlative studies
Study: NCT01907360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLD200 (methylphenidate hydrochloride)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLD200 (methylphenidate hydrochloride)
Study: NCT03583177

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention
Study: NCT03747198

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: methylsulfonylmethane
Description: Subjects will be given 2 g/day methylsulfonylmethane.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be given 2 g/day placebo (rice flour).
Study: NCT03090230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Relay Pro Thoracic Stent-Graft System
Description: RelayPro Thoracic Stent-Grafts are designed for the management of patients with aneurysms and penetrating ulcers within the descending thoracic aorta (DTA). The device is designed specifically for use in the thoracic aorta.
Study: NCT03322748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual physical therapy+ strengthening of lower limbs muscles
Description: Experimental group will perform usual physical therapy plus 3 series of isometric contractions of ankle plantarflexor and Hamstring muscles bilaterally, each lasting 5 seconds.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual physical therapy
Description: Usual physical therapy
Study: NCT01848951

Intervention type: DRUG
Intervention: Epidural
Description: The skin will be disinfected with 2% chlorhexidine. Under sterile technique, the epidural will be placed. Epidural catheter will be placed at thoracic vertebral levels T5 to T10. Level chosen as clinically indicated. The epidural solution should contain institution's standard solution of Bupivicaine 0.05% and hydromorphone 10 mcg/cc. However, solution type should be clinically indicated.

Intervention type: DRUG
Intervention: TAP Block
Description: The skin will be disinfected with 2% chlorhexidine. The bilateral dual TAP infiltrative blocks will be placed using high-frequency ultrasound. The TAP blocks will be performed using lipospheric bupivacaine (Exparel) with the following dosing regimen.A 266mg (20cc) vial of lipospheric bupivacaine will be equally into 2 30 ml syringes using strict sterile technique. The solution will be diluted in each syringe with 20cc preservative free sterile 0.9% normal saline to a total volume of 30 ml in each syringe. Once the transversus abdominal plane is identified then a 5-10 ml of plain 0.9% normal saline will be injected to open the fascial plane. Once the plane is opened then the 15cc of diluted lipospheric bupivacaine will be administered under direct ultrasound visualization in all 4 TAP quadrants (subcostal position x2 and lateral position x2)
Study: NCT04983641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-Visit Messages
Description: Patients in both experimental arms (E-mail and Digital Patient Portal MyChart) were sent pre-visit messages regarding PROMIS form completion via each respective modality at 1 week and also 3 days prior to their respective Orthopaedic clinic visits

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-Visit Messages
Description: Patients in both experimental arms (E-mail and Digital Patient Portal MyChart) were sent pre-visit messages regarding PROMIS form completion via each respective modality at 1 week and also 3 days prior to their respective Orthopaedic clinic visits
Study: NCT01744223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-501 dose 1
Description: Subjects will receive 2x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Dimerizer drug administered by intravenous infusion in those subjects who develop GVHD after infusion of BPX-501 cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Dimerizer drug administered by intravenous infusion in those subjects who develop GVHD after infusion of BPX-501 cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Dimerizer drug administered by intravenous infusion in those subjects who develop GVHD after infusion of BPX-501 cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Dimerizer drug administered by intravenous infusion in those subjects who develop GVHD after infusion of BPX-501 cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-501 dose 2
Description: Subjects will receive 5x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-501 dose 3
Description: Subjects will receive 1x10E6 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-501 dose 4
Description: Subjects will receive 3x10E6 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SCT
Description: all subjects will receive an alpha beta depleted donor transplant as part of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SCT
Description: all subjects will receive an alpha beta depleted donor transplant as part of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SCT
Description: all subjects will receive an alpha beta depleted donor transplant as part of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SCT
Description: all subjects will receive an alpha beta depleted donor transplant as part of treatment
Study: NCT01777269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride plus tamsulosin
Description: Take 1 capsule daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take one capsule daily
Study: NCT04309344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WEREWOLF COBLATION System
Description: The bipolar radiofrequency-based chondroplasty device is used in the COBLATION mode (yellow) with The WEREWOLF system and the wand FLOW 50 in Lo mode (low) which are approved by the FDA for chondroplasty and debridement of the articular cartilage; fibrillations were removed and the surface was smoothed. This low energy and low suction setting minimizes damage to healthy chondrocytes surrounding and is therefore the preferred setting for the removal of articular cartilage.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: mechanical debridement
Study: NCT03120767

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk and Resilience
Description: The Risk and Resilience course is a 14-week undergraduate seminar that is grounded in the current understanding of adolescent and young adult development, neuroscience, and positive psychology. Students will learn about key areas proven to enhance wellness, including communication, executive functioning, social support, self-efficacy, emotion regulation, and sense of purpose. Students will learn about healthy exercise, nutrition, and sleep habits, and develop skills in core components of cognitive-behavior therapy, mindfulness, and organizational skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Risk and Resilience
Description: The Risk and Resilience course is a 14-week undergraduate seminar that is grounded in the current understanding of adolescent and young adult development, neuroscience, and positive psychology. Students will learn about key areas proven to enhance wellness, including communication, executive functioning, social support, self-efficacy, emotion regulation, and sense of purpose. Students will learn about healthy exercise, nutrition, and sleep habits, and develop skills in core components of cognitive-behavior therapy, mindfulness, and organizational skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coordinated Wellness Programming
Description: During the Fall of 2017, wellness activities will be provided within Founders Hall that support the theories and skills being taught in the Risk and Resilience course occurring in the same semester.
Study: NCT01775267

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Associating liver partition and portal vein ligation for staged hepatectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Portal vein embolization or ligation
Study: NCT02636179

Intervention type: OTHER
Intervention: Comparative epidemiological survey
Description: The method used to select the control group will be the random sampling of eligible schools. It will be defined according to the place of schooling of the historic cohort of children. The children will be matched as close as possible based on sex, age, school class and type of school (public/private).
Study: NCT01084655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: TAK-700 with docetaxel and prednisone on a continuous schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: TAK-700 with docetaxel and prednisone on a continuous schedule.